News &amp; Updates

Both symptomatic and asymptomatic hypotension are associated with worse outcomes during treatment with either enalapril or sacubitril/valsartan, but the benefits derived from the combination therapy are maintained or even improved in heart failure (HF) patients with hypotension, a study has shown.

Sacubitril/valsartan maintains efficacy, safety in HF patients with hypotension

31 Oct 2024

Lacosamide safe, efficacious for long-term seizure control in idiopathic generalized epilepsy

In patients with idiopathic generalized epilepsy, adjunctive lacosamide treatment in the long term may safely reduce the frequency of generalized onset tonic–clonic seizures (GTCS), as shown in the open-label extension EP0012 trial.

Lacosamide safe, efficacious for long-term seizure control in idiopathic generalized epilepsy

Acoramidis boosts clinical outcomes in ATTR-CM

31 Oct 2024 by

Treatment with the investigational agent acoramidis significantly reduced all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at 30 months for patients with transthyretin amyloid cardiomyopathy (ATTR-CM), according to a post hoc analysis of the phase III ATTRibute-CM trial presented at HFSA 2024.

Acoramidis boosts clinical outcomes in ATTR-CM

Cardiac biomarker profile in ATTR-CM looks good with vutrisiran

In the treatment of patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), the use of the small interfering ribonucleic acid (siRNA) vutrisiran helps reduce and maintain the stability of NT-proBNP and troponin I—biomarkers associated with increased mortality in this population, as reported in a late-breaking clinical research presentation in HFSA 2024.

Cardiac biomarker profile in ATTR-CM looks good with vutrisiran

Mavacamten mends cardiac biomarkers in patients with HFpEF

Treatment with mavacamten results in improvements in cardiac biomarkers of wall stress and injury, as shown by reduced NT-proBNP and troponin, without sustained left ventricular ejection fraction (LVEF) reductions, according to the preliminary findings of the EMBARK-HFpEF trial.

Mavacamten mends cardiac biomarkers in patients with HFpEF

Aficamten improves clinical outcomes in obstructive HCM

Patients with obstructive hypertrophic cardiomyopathy (oHCM) can derive broad clinical benefits from treatment with aficamten, which include complete haemodynamic response and improved exercise capacity among others, as shown by the results of the SEQUOIA-HCM study.

Aficamten improves clinical outcomes in obstructive HCM

30 Oct 2024

Spermatogenesis induction successful with gonadotropin treatment

Gonadotropin treatment helps promote sperm production, especially in most men with pathological gonadotropin deficiency, according to the results of a systematic review and meta-analysis.

Spermatogenesis induction successful with gonadotropin treatment

Novel HU6 reduces weight without muscle loss in patients with obesity-related HFpEF

Treatment with HU6, a novel, first-in-class controlled metabolic accelerator, significantly reduces body weight while preserving lean body mass in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), according to the HuMAIN-HFpEF* trial presented at HFSA 2024.

Novel HU6 reduces weight without muscle loss in patients with obesity-related HFpEF